---
canonical_name: LSD Analogues
alternate_names: Lysergamides, Lysergic Acid Diethylamide Analogues, LSD Derivatives, LSD Prodrugs, 1P-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, ALD-52, ETH-LAD, AL-LAD, LSZ, 2-Bromo-LSD, BOL-148, JRT, Tabernanthalog
canonical_topic: LSD Analogues for Health & Longevity
short_topic_lc: lsd_analogues
creation_date: 2026-0705-1100
creator_ai_fullname: Opus 4.8
ep_keywords: Psychedelics, Lysergamides, Serotonergic Psychedelics, Classic Psychedelics, 5-HT2A Agonists
---

# LSD Analogues for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/30/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Lysergamides, Lysergic Acid Diethylamide Analogues, LSD Derivatives, LSD Prodrugs, 1P-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, ALD-52, ETH-LAD, AL-LAD, LSZ, 2-Bromo-LSD, BOL-148, JRT, Tabernanthalog


## Motivation

<!-- This motivation section was written after the rest of the document was completed, so that it reflects the full scope of the review. -->

LSD analogues are chemical relatives of lysergic acid diethylamide (LSD), built by making small changes to the LSD molecule. They fall into two broad families with very different purposes. The first are "research chemicals" sold online — such as 1P-LSD and ALD-52 — that act much like LSD itself, often because the body converts them back into LSD. The second are purpose-engineered molecules, such as 2-bromo-LSD and the experimental compound JRT, designed to keep LSD's effects on brain cell growth while removing or reducing the trip.

For decades these molecules were chemical curiosities. Renewed scientific interest in classic psychedelics for mood and addiction, together with a wave of online "legal high" lysergamides appearing after national LSD bans, has pushed both families into the spotlight. A single headline finding — that a non-tripping LSD relative can still reshape brain connections in animals — has energized drug developers.

This review examines what is known about LSD analogues as a group: how they work, what benefits and risks the evidence supports, how they are used, and where the research is heading.


**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level expert and primary-source material that introduces LSD analogues and the engineering of safer LSD-like molecules.

<!-- A real-time web search was performed across the prioritized expert platforms (Rhonda Patrick/foundmyfitness.com, Peter Attia/peterattiamd.com, Andrew Huberman/hubermanlab.com, Chris Kresser/chriskresser.com, Life Extension/lifeextension.com) and the general web for "LSD analogues", "lysergamides", "non-hallucinogenic LSD analog", "1P-LSD", "2-bromo-LSD" and "JRT". The prioritized experts have substantial material on LSD and classic psychedelics broadly, but none publish content focused specifically on the LSD-analogue class; their general psychedelic material does not discuss the analogues by name in depth. The strongest directly relevant high-level sources are primary research papers and a narrative review describing the analogue class itself, listed below. -->

- [A non-hallucinogenic psychedelic analogue with therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/33299186/) - Cameron et al., 2021

  This foundational paper introduces tabernanthalog, a water-soluble, non-hallucinogenic analogue engineered from a psychedelic alkaloid, and demonstrates that careful chemical design can preserve brain-cell-growth effects while removing the trip — the central idea behind the engineered LSD-analogue field.

- [A non-hallucinogenic LSD analog with therapeutic potential for mood disorders](https://pubmed.ncbi.nlm.nih.gov/36884348/) - Lewis et al., 2023

  This study profiles 2-bromo-LSD across more than 30 receptors and shows it acts like LSD on the key serotonin target while avoiding the heart-valve receptor and the head-twitch behavior linked to hallucinations, making it a leading template for a safer LSD relative.

- [Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential](https://pubmed.ncbi.nlm.nih.gov/40228113/) - Tuck et al., 2025

  This paper reports the design and synthesis of JRT, a close structural analogue of LSD that promotes brain connection growth and improves depression- and cognition-related behavior in rodents without worsening psychosis-related signals, illustrating the current frontier of LSD-analogue engineering.

- [Serotonin 2A Receptor Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants](https://pubmed.ncbi.nlm.nih.gov/38033123/) - Duan et al., 2024

  This narrative review maps the structure-activity relationships across psychedelic and non-hallucinogenic serotonin-receptor activators, providing a clear high-level framework for understanding how small molecular tweaks separate the therapeutic from the hallucinogenic effects of LSD-like compounds.

- [Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)](https://pubmed.ncbi.nlm.nih.gov/38569566/) - Kavanagh et al., 2025

  This paper characterizes a representative "research chemical" lysergamide and explains the prodrug concept — that compounds such as ALD-52 and 1P-LSD are hydrolyzed in the body back into LSD — which is essential context for understanding the recreational analogue family.

_Note: No content focused specifically on the LSD-analogue class was found from the prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension). Their available material covers LSD and classic psychedelics generally rather than the analogues by name, so it was not eligible for this list. The five sources above are the most directly relevant high-quality items identified._


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "LSD analogues", "1P-LSD" and related terms. Grokipedia hosts dedicated pages for many individual LSD analogues (e.g., 1P-LSD, 1cP-LSD, 1D-LSD, 1V-LSD, 1S-LSD, 1P-BOL-148) but no single page for the analogue class as a whole. The 1P-LSD page is listed as the most representative dedicated analogue entry. -->

[1P-LSD](https://grokipedia.com/page/1P-LSD) - Grokipedia

This is Grokipedia's dedicated page for 1P-LSD, the most widely encountered LSD analogue; it covers the compound's chemistry, prodrug behavior, effects, and legal status, serving as a representative entry for the broader analogue class.


## Examine

<!-- examine.com was searched directly using the browser tool for "LSD analogues" and "1P-LSD". Examine has no page for the LSD-analogue class and no analogue-specific pages; it maintains a dedicated entry only for the parent compound, LSD. That parent page is cited below with a note, since it is the closest directly relevant Examine resource. -->

[LSD](https://examine.com/other/lsd/) - Examine

Examine does not maintain a page for the LSD-analogue class; its dedicated LSD page is the closest relevant resource and summarizes the evidence on the parent compound, which most analogues either mimic or convert into.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "LSD" and "LSD analogues". ConsumerLab tests dietary supplements, vitamins, and consumer health products; it does not cover controlled psychedelics or research-chemical lysergamides, and no article exists. -->

No ConsumerLab article exists for LSD analogues. ConsumerLab focuses on testing dietary supplements and consumer health products and does not cover controlled psychedelic substances or research-chemical lysergamides.


## Systematic Reviews

This section summarizes systematic reviews and meta-analyses most relevant to LSD analogues and the parent compound from which most analogues derive their activity.

- [Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials](https://pubmed.ncbi.nlm.nih.gov/40700269/) - Castro et al., 2025

  This is the only systematic review devoted to a specific LSD analogue (LSA, the naturally occurring lysergamide from morning-glory and Hawaiian baby woodrose seeds); it synthesizes 17 human studies on its effects, documents serious harms such as psychosis and hypertension, and notes preliminary signals for cluster headache.

- [Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review](https://pubmed.ncbi.nlm.nih.gov/40354769/) - Chen et al., 2025

  This review collects all published preclinical and clinical evidence on non-hallucinogenic psychedelics — the engineered analogue family that includes LSD-derived candidates — finding consistent antidepressant-like effects in animals without the head-twitch response, but as yet no controlled human trials.

- [Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/39230883/) - Hinkle et al., 2024

  This meta-analysis of 214 studies (3,504 participants) quantifies adverse events for LSD and other classic psychedelics in clinical settings, providing the best available risk benchmark for analogues that act like LSD or convert into it.

- [Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies](https://pubmed.ncbi.nlm.nih.gov/39592825/) - Sabé et al., 2025

  This review estimates the incidence of psychedelic-induced psychosis (about 0.2–0.6% in trials) and its relationship to later schizophrenia, directly informing the psychosis risk that motivates the development of non-hallucinogenic LSD analogues.

- [Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes](https://pubmed.ncbi.nlm.nih.gov/40058407/) - Modzelewski et al., 2025

  This review characterizes the side-effect profile of low-dose LSD (the dosing pattern most associated with recreational LSD-analogue use), reporting mostly mild, dose-dependent effects such as raised blood pressure, anxiety, and short-term cognitive impairment.


## Mechanism of Action

LSD analogues act mainly through the same target as LSD itself: the serotonin 2A receptor (5-HT2A, a brain protein that, when switched on, drives the visual and mind-altering effects of psychedelics). Activation of this receptor sets off a downstream cascade — TrkB (a growth-factor receptor), mTOR (a master regulator of cell growth, short for mechanistic target of rapamycin), and AMPA receptors (the brain's main fast-signaling glutamate receptors) — that increases the growth of dendritic spines, the tiny connection points between brain cells. This growth-promoting capacity is termed "psychoplastogenic."

The analogues split mechanistically into two groups:

The "research chemical" lysergamides (1P-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, ALD-52) are largely prodrugs — inactive or weakly active until the body's enzymes cleave a chemical group attached to the molecule's nitrogen, releasing LSD itself. Their effects therefore closely track LSD, scaled by how efficiently they are converted. Other structural analogues alter the diethylamide side chain (LSZ, ETH-LAD, AL-LAD) and act directly at 5-HT2A with potencies that differ from LSD.

The engineered non-hallucinogenic analogues exploit a competing mechanistic idea: that the brain-growth and antidepressant effects can be separated from the hallucination. 2-Bromo-LSD and JRT activate 5-HT2A and promote spine growth while producing little or no head-twitch response (the rodent proxy for hallucinations), suggesting that distinct signaling pathways or "biased agonism" downstream of the same receptor drive the therapeutic versus perceptual effects. Whether a hallucination is strictly required for lasting benefit in humans remains genuinely contested, and both views are represented in the literature.

As pharmacological compounds, the analogues vary widely. LSD itself has a half-life of roughly 3–4 hours with effects lasting 8–12 hours, is metabolized primarily by liver enzymes including CYP-family oxidases (the cytochrome P450 family that processes most drugs), and is highly potent (active in the microgram range). Prodrug analogues add the time needed for enzymatic conversion; longer acyl chains (as in 1DD-LSD) appear to slow conversion and may sequester the drug in fat, potentially extending duration. Tissue distribution data for most analogues are sparse.


## Historical Context & Evolution

LSD was first synthesized by Albert Hofmann at Sandoz in 1938, with its psychoactivity discovered in 1943. From the 1950s, Sandoz distributed LSD and several early analogues to researchers worldwide, and chemists synthesized the first deliberate analogues — including ALD-52 (1-acetyl-LSD) and BOL-148 (2-bromo-LSD) — in the 1950s and 1960s to probe structure-activity relationships and to find compounds with separated effects. BOL-148, notably, was an early example of a near-non-hallucinogenic lysergamide.

The original intended uses were investigative and therapeutic: LSD and its relatives were studied as tools to model psychosis, as adjuncts to psychotherapy, and for alcoholism and end-of-life distress. This first research era largely ended after LSD was placed under strict international control in the late 1960s and early 1970s.

The modern analogue story has two threads. The first is the "research chemical" wave: beginning around the 2010s, vendors began selling novel lysergamides such as 1P-LSD, ALD-52, and later 1cP-LSD and 1V-LSD online, deliberately structured to fall outside existing drug schedules ("legal highs"). The actual findings from forensic and pharmacological characterization showed many of these act as LSD prodrugs, prompting analogue-based legal controls in several countries.

The second thread is the deliberate engineering of non-hallucinogenic analogues. The 2021 description of tabernanthalog and subsequent LSD-specific compounds (2-bromo-LSD, JRT) reflects a shift toward separating therapeutic neuroplasticity from the psychedelic experience. The reasons these molecules came to be considered for health optimization include the renewed clinical promise of psychedelics for depression and addiction combined with the practical and safety limits of the hallucinatory experience.

Scientific opinion continues to evolve. Earlier assumptions that hallucinations are necessary for benefit, and that a glutamate burst is required for neuroplasticity, have both been challenged by recent analogue work; the field has not settled on a final view, and new evidence is emerging on multiple sides.


## Expected Benefits

The benefits below are framed for risk-aware, proactive adults considering this area for health optimization. It is important to note that for the engineered non-hallucinogenic analogues, essentially all evidence is preclinical (animal and cell studies), and for the recreational lysergamides, benefits are extrapolated from LSD and from anecdotal report; no LSD analogue is an approved therapy.

A dedicated search of clinical, preclinical, and expert sources was performed to compile the complete benefit profile before writing this section.

### High 🟩 🟩 🟩

(No benefits of LSD analogues meet the High evidence bar. No analogue has demonstrated a benefit in adequately powered, replicated human randomized controlled trials.)

### Medium 🟩 🟩

#### Promotion of Neuroplasticity (Brain Connection Growth)

Across multiple independent rodent and cell studies, LSD analogues — both prodrug lysergamides (which release LSD) and engineered non-hallucinogenic compounds — increase dendritic spine density and dendritic branching in the cortex via the 5-HT2A→TrkB→mTOR pathway. This "psychoplastogenic" effect is the most consistently replicated property of the class and is proposed as the basis for antidepressant and pro-cognitive actions. The evidence is strong preclinically but not yet confirmed in humans, which caps the grade at Medium.

**Magnitude:** In cultured cortical neurons, LSD-like analogues increase dendritic spine density on the order of 1.5–2x versus vehicle in published assays; human magnitude is unknown.

### Low 🟩

#### Antidepressant-Like Effects

Engineered non-hallucinogenic analogues (2-bromo-LSD, JRT, tabernanthalog) produce antidepressant-like behavior in rodent models such as the forced swim test and reverse the behavioral effects of chronic stress, with effects blocked by a 5-HT2A antagonist. A systematic review of non-hallucinogenic psychedelics found consistent animal antidepressant signals plus a single human case report; controlled human data are absent, holding this at Low.

**Magnitude:** Not quantified in available studies.

#### Reduction of Addiction-Related Behavior

The engineered analogue tabernanthalog reduced alcohol- and heroin-seeking behavior in rodents, echoing the anti-addictive reputation of the parent psychedelic class. This signal is mechanistically plausible (neuroplasticity in addiction circuits) but limited to animal models for the analogues specifically.

**Magnitude:** Not quantified in available studies.

#### Cluster Headache Relief

Lysergamides as a chemical family have a long-standing association with cluster headache relief, and the systematic review of the LSD analogue LSA noted preliminary evidence for this use. Non-hallucinogenic candidate BOL-148 (2-bromo-LSD) has historically been explored for cluster headache. Evidence specific to analogues is sparse and largely uncontrolled.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Anxiety and End-of-Life Distress Reduction

By analogy to LSD, which is in active trials for anxiety and palliative-care distress, analogues that convert to LSD or mimic its receptor profile might offer similar benefits. No controlled data exist for any analogue in these indications; the basis is mechanistic and extrapolative only.

#### Pro-Cognitive and "Microdosing" Benefits

Anecdotal reports surrounding recreational lysergamides (used at low, sub-perceptual doses much like LSD microdosing) claim improvements in mood, focus, and creativity. Controlled microdosing studies of LSD itself have largely failed to separate these effects from placebo, and no controlled analogue data exist, so this remains speculative and rests on anecdote.

#### Longevity-Relevant Neuroprotection

The neuroplasticity-promoting and possibly anti-inflammatory actions of 5-HT2A activators have prompted speculation about neuroprotective or healthy-aging benefits. This is currently a hypothesis without direct evidence for any LSD analogue.


## Benefit-Modifying Factors

* **Prodrug conversion efficiency:** For the lysergamide research chemicals, benefits depend on how completely the body cleaves the molecule to release LSD; longer acyl chains (e.g., 1DD-LSD) convert less efficiently and may blunt or delay effects.

* **Genetic polymorphisms:** Variation in serotonin-system genes (e.g., HTR2A, encoding the 5-HT2A receptor that these compounds target) and in drug-metabolizing CYP enzymes (the cytochrome P450 enzymes that process most drugs) could plausibly alter response, though analogue-specific pharmacogenetic data are lacking.

* **Baseline biomarker and mood state:** As with classic psychedelics, baseline depression severity and trait factors influence the magnitude of mood benefit; greater baseline burden tends to predict larger improvement in psychedelic trials.

* **Sex-based differences:** Sex differences in serotonergic signaling and in psychedelic response have been reported for classic psychedelics, but no analogue-specific human data quantify them.

* **Pre-existing health conditions:** A personal or family history of psychotic illness reduces eligibility and likely the favorable benefit-risk balance for hallucinogenic analogues; the non-hallucinogenic analogues are specifically being designed for such populations.

* **Age:** Older adults at the upper end of the target range may experience altered drug metabolism and greater cardiovascular sensitivity, potentially shifting the benefit-risk balance even where central effects are preserved.


## Potential Risks & Side Effects

Risks below are framed for the proactive, risk-aware adult. A dedicated search of drug-reference and pharmacovigilance sources, plus the systematic-review literature, was performed to compile the complete risk profile. A defining hazard of the analogue class is uncertainty itself: most recreational lysergamides have never been formally tested for safety in humans, and dosing/purity are highly variable.

### High 🟥 🟥 🟥

#### Dose and Purity Uncertainty (Research-Chemical Lysergamides)

The most consequential risk of the recreational analogue family is that products are unregulated "research chemicals" of unknown purity and potency, frequently mislabeled, and sometimes sold as blotter that delivers an unpredictable dose. Forensic analyses repeatedly identify unexpected analogues and impurities in seized products. This variability directly drives overdose, unexpected duration, and adverse reactions, and is supported by consistent forensic-toxicology findings.

**Magnitude:** Microgram-level potency means a several-fold dosing error is easy; analyzed products have shown wide content variability and the presence of undeclared analogues.

#### Acute Psychological Distress ("Bad Trips")

Hallucinogenic analogues — those that act like or convert to LSD — can produce intense anxiety, panic, paranoia, confusion, and frightening perceptual experiences during acute intoxication. Meta-analytic data on classic psychedelics in controlled settings show these acute non-serious events (anxiety, paranoia) are common, and they are typically more severe and less manageable in uncontrolled recreational settings where most analogue use occurs.

**Magnitude:** Anxiety and related acute reactions are among the most frequently reported adverse events in psychedelic studies, occurring in a substantial minority of high-dose exposures.

#### Cardiovascular Stimulation

LSD-like compounds raise blood pressure and heart rate. The systematic review of low-dose LSD identified increased blood pressure as a common side effect even at microdoses, and severe hypertension has been documented with the LSD analogue LSA. This poses meaningful risk for individuals with cardiovascular disease.

**Magnitude:** Transient increases in systolic blood pressure and heart rate are commonly reported; severe hypertensive events have been documented in case reports for lysergamides.

### Medium 🟥 🟥

#### Cardiac Valve Risk (5-HT2B Activation)

Many ergot-derived and lysergamide compounds activate the 5-HT2B receptor, chronic stimulation of which is linked to heart-valve thickening (valvulopathy) — the mechanism behind withdrawn appetite-suppressant drugs and the ergot dopamine agonists. This risk is most relevant with repeated or chronic dosing and is a major reason engineered analogues such as 2-bromo-LSD are specifically designed to avoid 5-HT2B.

**Magnitude:** Not quantified for LSD analogues specifically; risk is inferred from the established valvulopathy of chronic 5-HT2B agonists.

#### Psychosis and Prolonged Psychiatric Reactions

In vulnerable individuals, psychedelics can trigger prolonged psychotic episodes; a meta-analysis estimated psychedelic-induced psychosis at roughly 0.2–0.6% in trial settings, with a subset later diagnosed with schizophrenia. Because analogue use is largely unsupervised, screening for personal/family psychosis history is absent, plausibly raising real-world incidence above trial estimates.

**Magnitude:** Approximately 0.2–0.6% incidence in controlled trials of classic psychedelics; higher uncertainty in uncontrolled analogue use.

### Low 🟥

#### Hallucinogen Persisting Perception Disorder (HPPD)

Some users of LSD and its analogues report persistent visual disturbances (e.g., trails, halos) lasting after the drug has worn off. In contemporary controlled trials of classic psychedelics this has not been reported, but it appears in recreational contexts, which describe most analogue exposure.

**Magnitude:** Not quantified in available studies; reported in recreational but not contemporary clinical settings.

#### Nausea, Headache, Dizziness, and Fatigue

Common, generally mild acute physical side effects shared across the lysergamide class, mirroring the parent compound. Meta-analysis of classic psychedelics found headache, nausea, dizziness, and fatigue to be among the most frequent non-serious events.

**Magnitude:** Frequently reported but generally mild and self-limited within the acute drug window.

### Speculative 🟨

#### Long-Term Organ or Metabolic Toxicity from Novel Analogues

Because many lysergamides are recently introduced and never studied chronically in humans, the possibility of unrecognized long-term toxicity (e.g., from lipophilic analogues sequestering in tissue, or from undocumented metabolites) cannot be excluded. The basis is mechanistic and precautionary; no controlled human data exist.

#### Unpredictable Drug–Drug Interactions

The metabolic and receptor profiles of newer analogues are incompletely mapped, so the potential for unexpected interactions (e.g., with serotonergic medications) is plausible but undocumented for most compounds.


## Risk-Modifying Factors

* **Genetic polymorphisms:** Variants in CYP enzymes (cytochrome P450 drug-metabolizing enzymes) could alter how quickly an analogue or its released LSD is cleared, affecting both duration and adverse-effect intensity; HTR2A and HTR2B variants (genes encoding the 5-HT2A and 5-HT2B serotonin receptors, the targets driving perceptual effects and heart-valve risk respectively) may modify perceptual and cardiac risk respectively.

* **Baseline biomarker levels:** Elevated baseline blood pressure or known cardiac valve abnormalities raise the cardiovascular and valvulopathy risk from 5-HT2A/5-HT2B-active analogues.

* **Sex-based differences:** Sex differences in serotonergic pharmacology and cardiovascular reactivity may modify risk, but analogue-specific quantitative data are not available.

* **Pre-existing health conditions:** Personal or family history of psychotic or bipolar illness markedly raises the risk of triggering psychosis or mania; cardiovascular disease raises the risk from blood-pressure elevation; liver impairment may slow metabolism of prodrug analogues.

* **Age:** Older adults may have reduced hepatic clearance and greater cardiovascular vulnerability, increasing the chance of prolonged effects and hemodynamic adverse events even at the upper end of the target audience age range.


## Key Interactions & Contraindications

* **Serotonergic antidepressants (SSRIs such as fluoxetine/sertraline, SNRIs such as venlafaxine, and MAOIs such as phenelzine):** Caution to absolute contraindication. Combining serotonin-raising drugs with 5-HT2A-active analogues risks serotonin syndrome (dangerous serotonin excess causing agitation, fever, rapid heart rate); MAOIs in particular can dangerously potentiate effects. Monitor or avoid; do not combine without specialist oversight.

* **Lithium and tricyclic antidepressants:** Caution. Case reports link lithium plus psychedelics to seizures; both classes may amplify or unpredictably alter the response. Separation or avoidance is advised.

* **Other serotonergic / 5-HT2A agents and triptans (OTC and prescription):** Caution. Migraine triptans (sumatriptan) and other ergot derivatives share serotonergic and vasoconstrictive activity; co-use raises cardiovascular and serotonin-related risk.

* **Other vasopressors and stimulants (OTC decongestants such as pseudoephedrine; caffeine in excess; recreational stimulants):** Caution. Additive blood-pressure and heart-rate elevation increases cardiovascular risk; the consequence is hypertension and tachycardia.

* **Supplements with serotonergic or blood-pressure effects:** Caution. 5-HTP, St. John's wort, and tryptophan add serotonergic load (serotonin syndrome risk); stimulant herbs (e.g., synephrine, high-dose yohimbine) add to blood-pressure elevation. These are examples of supplements with additive effects on the same systems the analogues act upon.

* **CYP-modulating drugs and foods (e.g., CYP3A4 inhibitors such as ketoconazole, ritonavir, and grapefruit juice):** Caution. Because LSD and prodrug analogues are metabolized in part by CYP enzymes, strong inhibitors may prolong and intensify effects; the mitigating action is dose reduction and timing separation.

* **Populations who should avoid this intervention:** Individuals with a personal or family history of schizophrenia or other psychotic disorders, or bipolar disorder (mania risk); individuals with significant cardiovascular disease, uncontrolled hypertension, or known cardiac valvulopathy; those with recent myocardial infarction (<90 days); those who are pregnant or breastfeeding; and individuals with severe hepatic impairment (Child-Pugh Class C) given reliance on hepatic metabolism. These analogues are illegal or unapproved in most jurisdictions, which is itself a contraindication to non-research use.


## Risk Mitigation Strategies

* **Avoid unregulated research-chemical lysergamides:** Because purity and potency are unverifiable, the single most effective way to mitigate the dose-uncertainty and contamination risks is to not use unregulated online lysergamides; the only meaningfully risk-controlled exposure is within an authorized clinical trial.

* **Comprehensive screening before any exposure:** Screen for personal and family history of psychosis, bipolar disorder, and significant cardiovascular disease to prevent triggering psychosis, mania, or a cardiovascular event; this mirrors mandatory eligibility screening in psychedelic trials.

* **Cardiovascular baseline and monitoring:** Measure baseline blood pressure and, where chronic dosing is contemplated, screen for valve disease (echocardiography); this addresses the hypertension and 5-HT2B valvulopathy risks. Monitor blood pressure during acute exposure.

* **Medication reconciliation and washout:** Review all serotonergic drugs and supplements and observe appropriate washout (e.g., for MAOIs and high-dose SSRIs) to prevent serotonin syndrome and adverse potentiation; separate timing of CYP-inhibiting drugs.

* **Set, setting, and supervision:** For any hallucinogenic exposure, a controlled environment with a trained, sober monitor mitigates acute psychological distress ("bad trips") and injury; trial protocols use prolonged in-session supervision and follow-up.

* **Low starting dose with conservative titration:** Where exposure occurs in a research setting, beginning at a low dose with careful titration mitigates the risk of overwhelming acute reactions and unexpected potency, particularly given variable prodrug conversion.

* **Prefer non-hallucinogenic candidates where the goal is neuroplasticity:** For the specific risk of hallucination-related distress and psychosis, the engineered non-hallucinogenic analogues are being developed expressly to remove that hazard — though they remain investigational and unproven in humans.


## Therapeutic Protocol

No LSD analogue has an established, evidence-based therapeutic protocol in humans; what follows describes how leading practitioners and trial designers approach LSD-like compounds, since the recreational analogues are extrapolated from LSD and the engineered analogues are not yet in routine human use.

* **Conventional clinical-trial approach (parent compound and LSD-like analogues):** As used by leading academic groups (e.g., the University Hospital Basel psychopharmacology program led by Matthias Liechti), LSD is given as a single supervised oral dose under medical monitoring with extensive psychological preparation and integration sessions, in a controlled setting. This is the dominant model for any hallucinogenic lysergamide.

* **Integrative / psychotherapy-assisted approach:** An alternative emphasizes the drug as an adjunct to structured psychotherapy across preparation, dosing, and integration, rather than as a stand-alone pharmaceutical; this approach traces to mid-20th-century psycholytic therapy and is championed by parts of the contemporary psychedelic-therapy field. Neither approach is framed here as the default.

* **Engineered non-hallucinogenic approach:** For analogues such as JRT and tabernanthalog, the envisioned protocol is conventional take-home dosing without supervision (because no trip occurs), more like a standard antidepressant; this remains hypothetical pending human trials and is associated with the Delix Therapeutics / University of California, Davis (Olson group) development programs.

* **Best time of day:** Hallucinogenic analogues are taken in the morning because of their long duration (LSD effects last 8–12 hours), to avoid sleep disruption; non-hallucinogenic candidates would not carry this constraint.

* **Half-life considerations:** LSD's elimination half-life is roughly 3–4 hours, but perceptual effects outlast plasma levels; prodrug analogues add conversion time, and longer-chain analogues may act for longer. Dosing schedules must account for this extended and sometimes unpredictable duration.

* **Single versus split dosing:** Therapeutic psychedelic use employs a single discrete dose per session rather than split dosing; recreational microdosing of lysergamides uses small intermittent single doses (e.g., every few days), though this pattern lacks controlled support.

* **Genetic polymorphisms:** Pharmacogenetically relevant CYP variants and HTR2A genotype may influence response and dose needs in principle; no analogue-specific dosing adjustments are validated.

* **Sex-based differences:** No validated sex-specific dosing exists for any analogue; clinicians monitor response individually.

* **Age-related considerations:** Lower, more cautious dosing is prudent for older adults given altered metabolism and cardiovascular sensitivity, even within the target audience.

* **Baseline biomarkers:** Baseline blood pressure and mood-rating scales guide eligibility and response assessment in trial settings.

* **Pre-existing conditions:** Protocols exclude individuals with psychosis history and significant cardiac disease, and adjust supervision intensity for anxiety-prone individuals.


## Discontinuation & Cycling

* **Lifelong versus short-term use:** Psychedelic and analogue interventions are conceived as intermittent or short-course rather than continuous lifelong medication; the engineered non-hallucinogenic analogues, if developed, might be dosed more regularly like conventional antidepressants, but this is unestablished.

* **Withdrawal effects:** Classic psychedelics, including LSD, are not considered physically addictive and do not produce a defined physical withdrawal syndrome; abrupt discontinuation after intermittent use is not associated with dependence. Data specific to analogues are limited but expected to be similar for LSD-like compounds.

* **Tapering:** No tapering protocol is required for intermittent hallucinogenic use because there is no physical dependence; for any future daily-dosed non-hallucinogenic analogue, tapering needs would have to be determined in trials.

* **Tolerance and cycling:** LSD produces rapid tolerance ("tachyphylaxis") with repeated daily dosing, so escalating or daily use quickly loses effect; this is a key reason therapeutic and recreational use is spaced out. Spacing doses (cycling) is therefore effectively required to maintain efficacy of hallucinogenic analogues rather than being an optional enhancement.

* **Cross-tolerance:** Because many analogues act on or convert to LSD at the same receptor, cross-tolerance among lysergamides and with other classic psychedelics should be expected, reinforcing the need to space exposures.


## Sourcing and Quality

* **Regulatory and legality caveat:** The most important sourcing consideration is that recreational LSD analogues are unapproved research chemicals, illegal in many jurisdictions, and not manufactured to pharmaceutical standards; there is no legitimate consumer supply chain, and quality cannot be assured.

* **Purity and identity verification:** What to look for in principle would be third-party laboratory analysis of identity and purity, but in practice independent reagent testing of blotter is unreliable for distinguishing closely related lysergamides; forensic studies routinely find mislabeled products and undeclared analogues.

* **Pharmaceutical-grade material:** Within authorized research, the parent compound LSD is sourced as a defined salt (LSD tartrate) under good manufacturing practice; engineered analogues such as JRT and tabernanthalog are produced by their developers (e.g., Delix Therapeutics) as defined investigational compounds — the only context in which formulation quality is controlled.

* **Formulation:** LSD and lysergamides are light-, heat-, and oxidation-sensitive, degrading on storage; stability studies of ALD-52 and 1P-LSD confirm meaningful decomposition, so even where material is genuine, potency may decline unpredictably.


## Practical Considerations

* **Time to effect:** For hallucinogenic analogues that convert to or mimic LSD, acute effects begin within roughly 30–90 minutes and last 8–12 hours; any antidepressant benefit, by analogy to LSD trials, may build over days to weeks after a session. For engineered analogues, time-to-benefit in humans is unknown.

* **Common pitfalls:** The most common mistakes are dosing errors from unknown potency, combining with serotonergic medications, using in an unsupervised or unstable setting, and assuming a "legal" research chemical is therefore safe or quality-controlled.

* **Regulatory status:** No LSD analogue is approved for any medical use. LSD is a Schedule I substance in the United States and under equivalent strict control internationally; many analogues are explicitly scheduled or fall under analogue-control laws, and several countries enacted bans specifically targeting lysergamides such as 1P-LSD.

* **Cost and accessibility:** Legitimate access is essentially limited to enrollment in clinical research; the engineered therapeutic analogues are years from potential approval. Recreational research chemicals are comparatively inexpensive but carry the legal and safety problems above.


## Interaction with Foundational Habits

* **Sleep:** Direct and disruptive for hallucinogenic analogues. Their long duration and stimulating, mind-activating effects can prevent or fragment sleep if taken later in the day; morning dosing is used to protect the night's sleep. Non-hallucinogenic candidates are not expected to disturb sleep but this is unconfirmed.

* **Nutrition:** Indirect. LSD and prodrug analogues are partly metabolized by CYP enzymes, so foods that inhibit these enzymes (notably grapefruit juice) could prolong effects; taking on a relatively empty stomach is common to reduce nausea. No specific therapeutic diet is established. Lipophilic analogues may interact with body-fat stores, theoretically affecting duration.

* **Exercise:** Indirect/potentiating on the same systems. Both vigorous exercise and these compounds raise heart rate and blood pressure, so combining intense exercise with acute dosing could add cardiovascular strain; separating strenuous exercise from acute exposure is prudent. There is no evidence that the analogues blunt training adaptations.

* **Stress management:** Direct and bidirectional. Psychological set and stress strongly shape the acute experience of hallucinogenic analogues — high stress or anxiety raises the chance of a difficult experience, while preparation, calm setting, and integration practices improve outcomes. The proposed antidepressant mechanism (neuroplasticity reversing stress-induced changes) is itself stress-related, and analogues reversed chronic-stress effects in animal studies.


## Monitoring Protocol & Defining Success

Because no LSD analogue is an approved therapy, the monitoring below reflects the prudent parameters used in psychedelic clinical research and what a careful practitioner would track; it applies most directly to hallucinogenic, LSD-like analogues.

Baseline assessment before any exposure should include cardiovascular evaluation (blood pressure, and echocardiography if chronic 5-HT2B-active dosing is contemplated), a structured psychiatric history screening for psychosis and bipolar risk, a validated depression/anxiety rating scale, and a full medication and supplement review.

Ongoing monitoring in a session context includes continuous blood-pressure and heart-rate observation during acute intoxication, psychological monitoring throughout the experience, and follow-up mood assessment in the days and weeks afterward; for any repeated dosing, blood pressure and mood scales should be reassessed at each session and roughly every 1–3 months, with cardiac valve screening every 6–12 months if chronic exposure occurs.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood pressure | <120/80 mmHg | Detects hypertension that the drug can worsen | Measure at baseline and during acute exposure; conventional "normal" is <130/80 |
| Heart rate | 60–80 bpm resting | Tracks cardiovascular stimulation | Monitor continuously during acute effects |
| Depression/anxiety rating (e.g., MADRS/PHQ-9, GAD-7) | Score in remission range (e.g., PHQ-9 <5) | Defines therapeutic response | Administer at baseline and at follow-up timepoints; primary success measure |
| Echocardiogram (cardiac valves) | No valve thickening/regurgitation | Screens for 5-HT2B-related valvulopathy with chronic use | Only relevant for repeated/chronic dosing; baseline then every 6–12 months |
| Liver function (ALT/AST) | ALT/AST within optimal low-normal range | Liver clears prodrug analogues; flags impairment | Conventional upper limits may miss early dysfunction; fasting not required |
| Comprehensive metabolic panel | Within optimal functional ranges | General safety screen for organ function | Standard fasting morning draw; baseline and periodic |

Qualitative markers of success and tolerability include:

* Sustained improvement in mood, outlook, and motivation
* Reduced anxiety and rumination
* Cognitive clarity and absence of lingering perceptual disturbances (no HPPD symptoms)
* Quality and continuity of sleep after dosing
* Absence of distressing or destabilizing psychological after-effects


## Emerging Research

Research framed for proactive, health-oriented adults is advancing on two fronts: testing the parent compound and LSD-like analogues in humans, and developing non-hallucinogenic analogues toward the clinic. Both directions could strengthen or weaken the case for this class.

* **Direct LSD analogue pharmacokinetics (DDH-LSD vs LSD):** A study is directly comparing the LSD analogue didehydro-LSD (DDH-LSD) against LSD to determine effective dose, duration, and half-life — the most directly relevant ongoing analogue trial. [NCT07309471](https://clinicaltrials.gov/study/NCT07309471) (University Hospital Basel; ~24 participants; assesses effective DDH-LSD dose and comparative duration/elimination).

* **LSD-derived antidepressant program (Phase 3):** A late-stage program is testing an LSD-based investigational drug (DT120) in major depressive disorder and generalized anxiety disorder, which could establish whether LSD-class compounds work in large controlled trials. [NCT07592689](https://clinicaltrials.gov/study/NCT07592689) (Definium Therapeutics; Phase 3; ~165 participants; primary endpoint change in MADRS depression score at Week 6) and the anxiety arm [NCT06741228](https://clinicaltrials.gov/study/NCT06741228) (Phase 3; ~214 participants; HAM-A anxiety score at Week 12).

* **LSD for cluster headache:** Controlled trials are testing LSD for chronic cluster headache, the indication most associated with lysergamides and a key signal that could extend to analogues. [NCT03781128](https://clinicaltrials.gov/study/NCT03781128) (University Hospital Basel; Phase 2; ~30 participants; attack frequency and intensity) and [NCT05477459](https://clinicaltrials.gov/study/NCT05477459) (Radboud University; Phase 2; ~65 participants; weekly attack frequency).

* **LSD in palliative care:** A trial of LSD for anxiety and distress in palliative care could clarify benefit for end-of-life indications relevant to analogues. [NCT05883540](https://clinicaltrials.gov/study/NCT05883540) (University Hospital Basel; Phase 2; ~60 participants; state anxiety vs active placebo).

* **Mechanism of non-hallucinogenic neuroplasticity:** Research is clarifying how engineered analogues promote brain-cell growth; a 2025 study showed the psychoplastogen tabernanthalog drives neuroplasticity through the same 5-HT2A/TrkB/mTOR/AMPA pathway as psychedelics but without an immediate glutamate burst, challenging prior assumptions about what is required for benefit. [Aarrestad et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40760185/).

* **Engineered LSD analogue design (could strengthen the case):** Continued medicinal-chemistry work on JRT and related non-hallucinogenic LSD analogues aims to move candidates toward human testing for depression and cognition. [Tuck et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40228113/).

* **Polypharmacology mapping (could weaken or refine the case):** Broad receptor-profiling studies of psychedelics are revealing multiple drug targets and off-target effects that could either open new uses or surface new safety concerns for analogues. [Jain et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40683247/).


## Conclusion

LSD analogues are a chemically diverse family that splits into two very different groups. One group — online "research chemicals" such as 1P-LSD and ALD-52 — largely turns back into LSD in the body and carries all of LSD's effects plus the added danger of unknown purity and dose. The other group is purpose-built: molecules engineered to keep LSD's apparent benefit of helping brain cells form new connections while removing or reducing the trip.

The most consistent finding, repeated in animal and cell studies, is that these compounds promote brain-connection growth, which may underlie hints of antidepressant and anti-addiction effects. But the evidence is overwhelmingly preclinical. No analogue has shown a clear benefit in solid human trials, and the engineered, non-tripping versions remain experimental. Meanwhile the unregulated recreational analogues bring real hazards: unpredictable dosing, raised blood pressure, possible heart-valve strain with repeated use, and a small risk of triggering lasting psychiatric problems in vulnerable people.

The evidence base is early, uneven, and clouded by the fact that much of it comes from drug developers and from uncontrolled use. For now, the honest summary is genuine scientific promise paired with substantial uncertainty and meaningful risk, with the engineered analogues representing the most interesting but least proven direction.


**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**